CG Oncology
Developing cretostimogene for bladder cancer alongside contract fill-and-finish manufacturing.
$73.91
After-hours close−0.42 (−0.57%)
At close$74.33(−5.92%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 111.69%Insiders 6.05%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 88.20M · Float 65.82M · 74.6% free float
Institutions13F, as of Jun 30, 2026
245 holders · 98.51M shares · 39 new positions · 132 increased · 76 reduced · 39 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 8.51M | 9.65% | +1.53M | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 6.62M | 7.50% | −103.5K | Aug 14, 2026 |
| Decheng Capital LLC | 6.37M | 7.22% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.26M | 7.09% | +1.19M | Aug 7, 2026 |
| Wellington Management Group LLP | 5.32M | 6.04% | −46.5K | Aug 14, 2026 |
| FMR LLC | 4.16M | 4.72% | +396.6K | Aug 13, 2026 |
| Price T Rowe Associates Inc /MD/ | 3.81M | 4.31% | +152.0K | Aug 14, 2026 |
| TCG Crossover Management, LLC | 3.67M | 4.16% | 0 | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 8.30% | 6.98M | 13G | May 15, 2026 ↗ |
| T. Rowe Price Investment Management, Inc. | 8.00% | 6.72M | 13G | May 15, 2026 ↗ |
| Wellington Management Group LLP | 7.20% | 5.51M | 13G | Nov 12, 2025 ↗ |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 7.00% | 5.32M | 13G | Feb 14, 2025 ↗ |
| Juliet Tammenoms Bakkerincl. Patrick G. Enright, Longitude Prime Fund, L.P. +3 more | 6.00% | 4.66M | 13D | Sep 18, 2025 ↗ |
| BlackRock, Inc. | 5.30% | 3.57M | Nov 8, 2024 ↗ | |
| FMR LLC | 5.10% | 3.86M | 13G | Aug 6, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Hong Fang Song | director | 3.25M | 3.69% | Sep 4, 2025 |
| Brian Guan-Chyun Liu | director | 1.89M | 2.14% | Jun 29, 2026 |
| Arthur Kuan | director, officer: Chief Executive Officer | 198.9K | 0.23% | Mar 13, 2026 |
1 ten-percent owner holds 4.96M shares by Form 4, outside the officers-and-directors figure above · 2 people have not refiled in the last 18 months (3.3K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Leonard E. Postdirector | Sale | 1,000 | $74.54 | 0 |
| Jul 15, 2026 | Leonard E. Postdirector | Sale | 1,000 | $71.17 | 0 |
| Jul 10, 2026 | James Mulaydirector | Sale | 24,165 | $75.16 | 0 |
| Jun 25, 2026 | Brian Guan-Chyun Liudirector | Purchase | 371,085 | $66.87 | 1,886,236 |
| Jun 24, 2026 | Leonard E. Postdirector | Sale | 5,000 | $70.00 | 0 |
| Jun 22, 2026 | Leonard E. Postdirector | Sale | 5,000 | $65.00 | 0 |
| Jun 15, 2026 | James Mulaydirector | Sale | 1,310 | $60.12 | 0 |
| Jun 4, 2026 | Leonard E. Postdirector | Sale | 1,000 | $54.50 | 0 |
| Apr 17, 2026 | James Mulaydirector | Sale | 15,600 | $73.01 | 0 |
| Mar 16, 2026 | James Mulaydirector | Sale | 1,310 | $63.50 | 0 |
CongressHouse and Senate disclosures
Not reported.